SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it will report third quarter 2017 financial results on Thursday, November 2, 2017, after the financial markets close.
Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call at 2:00 p.m. PT (5:00 p.m. ET) on November 2, 2017, to discuss third quarter 2017 financial results and operational updates. A press release outlining the financial results will be publicly distributed before the call.
Individuals interested in listening to the conference call may do so by dialing (877) 556-5248 for domestic callers, or (720) 545-0029 for international callers. Please reference Conference ID 85402256. Interested parties may access the live teleconference in the Investors section of the company’s website at http://investors.fluidigm.com/events.cfm. The link will not be active until 1:45 p.m. PT (4:45 p.m. ET) on November 2, 2017.
A telephone replay of the teleconference will be available 90 minutes after the end of the call at (855) 859-2056 (domestic toll-free), or (404) 537-3406 (international toll), Conference ID 85402256. The conference call will also be archived on the Fluidigm Investors page at http://investors.fluidigm.com/.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
Contact:
Fluidigm Corporation
Ana Petrovic
Director, Corporate Development and Investor Relations
650 243 6628
[email protected]


Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 



